S-Gboxin is primarily investigated for its potential in targeting and inhibiting the growth of glioblastoma cells, a highly aggressive form of brain cancer. It works by disrupting the energy production in cancer cells, specifically by interfering with mitochondrial function, which is crucial for the survival and proliferation of these cells. This makes it a promising candidate for developing targeted therapies that could selectively kill cancer cells while sparing healthy tissues. Research is ongoing to explore its efficacy, safety, and potential use in combination with other treatments to improve outcomes for patients with glioblastoma.